It's called The Journal
Patients treated with tesamorelin for 52 weeks (T-T group) showed no change between Weeks 26 and 52 in mean trunk fat (increase of 0.1 kg in Study 1 and decrease of 0.5 kg in Study 2, respectively, compared with an increase of 1.4 kg in patients in the T-P group in Study 1 and an increase of 1.09 kg in Study 2, respectively) nor was there a change from Week 26 baseline in mean lean body mass (decrease of 0.1 kg in Study 1 and increase of 0.1 kg in Study 2, respectively, compared with a decrease of 1.8 kg in patients in the T-P group in Study 1 and a decrease of 1.7 kg in Study 2, respectively)
Is it symptom-modifying, or is it truly disease modifying
Hence, formulation challenges have also never been greater
In addition, they have identified many additional genes that are protective and aim to further explore these to see if there are any additional therapeutic possibilities suggested by their research
In experimental models, the peptide components associated with KLOW influence immune-cell trafficking by modulating inflammatory mediators, endothelial signaling, and chemotactic pathways
